BioMAP® Diversity PLUS® Panel for Broad Phenotypic Profiling

Clinically Relevant Phenotypic Data Prior to Entering the Clinic


Request a Quote

The Diversity PLUS Panel was built out of a need for better in vitro models of human disease and is used by leaders in the pharmaceutical industry to better understand their candidate drugs, from discovery to preclinical safety. Whether rank ordering or screening thousands of compounds, Diversity PLUS is a service that will provide the data on efficacy and safety to enable you to make better informed decisions and pick the right molecules to progress to the clinic.

Figure Legend: Trametinib (Mekinist™ or GSK-1120212), a MEK1/2 inhibitor approved for the treatment of metastatic melanoma, profiled at 4 concentrations (red, orange, yellow and green) in the BioMAP Diversity PLUS Panel. Trametinib decreased proliferation and increased VEGFR2 expression in two models of vascular inflammation (3C and 4H) and decrease PAI-1 in a lung inflammation model. These changes can be attributed to efficacy of Trametinib in patients. Additionally, decreases of IL-8 and increases in VCAM-1 have been identified as important signatures in drugs that are associated with infections or skin rash (respectively). The remaining annotated peaks represent biomarker readouts that demonstrate statistically significant change during treatment as compared to historical controls (the range of historical vehicle control data is represented by the grey region closest to the axis).

What is Diversity PLUS?

  • 12 individual BioMAP human primary cell-based co-culture systems which predictively model drug effects on multiple tissues and disease states
  • 148 clinically relevant biomarker readouts determined by careful curation of clinical data
  • Data from >4,500 reference compounds which underpin powerful and predictive bioinformatics tools

What can Diversity PLUS do for you?

BioMAP Diversity PLUS Panel Service Details
Service Compound profiling (chemical or biologics) of 148 biomarker readouts across 12 systems at 4 concentrations.
Examples of Analysis Performed Identification and biological interpretation of relevant biomarker activities that are increased or decreased in comparions to vehicle control.

Unsupervised search for a phenotypically similar compound from the BioMAP Database of more than 4,500 reference compounds, approved drugs, and experimental agents.

Benchmarking (optional). A direct comparison of test compound to a specified reference compound from the BioMAP Database.
Report Details A study report is provided that includes: Annotation of biomarker activities with respect to biological significance, profile plots, graphical overlays of test and reference compound profiles, results of similiarity search, and expert data interpretation and analysis.

Available Systems & Readouts

System ▲RelevanceCell TypeBiomarker Readout
/MphgCardiovascular Disease, Chronic Inflammation, RestenosisMacrophages + Venular endothelial cellsCCL2/MCP-1, CCL3/MIP-1 α, CD106/VCAM-1, CD40, CD62E/E-Selectin, CD69, CXCL8/IL-8, IL-1 α, M-CSF, sIL-10, SRB, SRB-Mphg
3CCardiovascular Disease, Chronic InflammationVenular endothelial cellsCCL2/MCP-1, CD106/VCAM-1, CD141/Thrombomodulin, CD142/Tissue Factor, CD54/ICAM-1, CD62E/E-Selectin, CD87/uPAR, CXCL8/IL-8, CXCL9/MIG, HLA-DR, Proliferation, SRB
4HAllergy, Asthma, AutoimmunityVenular endothelial cellsCCL2/MCP-1, CCL26/Eotaxin-3, CD106/VCAM-1, CD62P/P-Selectin, CD87/uPAR, SRB, VEGFR2
BE3CCOPD, Lung InflammationBronchial epithelial cellsCD54/ICAM-1, CD87/uPAR, CXCL10/IP-10, CXCL11/I-TAC, CXCL8/IL-8, CXCL9/MIG, EGFR, HLA-DR, IL-1 α, Keratin 8/18, MMP-1, MMP-9, PAI-I, SRB, tPA, uPA
BF4TAllergy, Asthma, Fibrosis, Lung InflammationBronchial epithelial cells + Dermal fibroblastsCCL2/MCP-1, CCL26/Eotaxin-3, CD106/VCAM-1, CD54/ICAM-1, CD90, CXCL8/IL-8, IL-1 α, Keratin 8/18, MMP-1, MMP-3, MMP-9, PAI-I, SRB, tPA, uPA
BTAllergy, Asthma, Autoimmunity, OncologyB cells + Peripheral blood mononuclear cellsB cell Proliferation, PBMC Cytotoxicity, Secreted IgG, sIL-17A, sIL-17F, sIL-2, sIL-6, sTNF-α
CASM3CCardiovascular Inflammation, RestenosisCoronary artery smooth muscle cellsCCL2/MCP-1, CD106/VCAM-1, CD141/Thrombomodulin, CD142/Tissue Factor, CD87/uPAR, CXCL8/IL-8, CXCL9/MIG, HLA-DR, IL-6, LDLR, M-CSF, PAI-I, Proliferation, Serum Amyloid A, SRB
HDF3CGFChronic Inflammation, FibrosisDermal fibroblastsCCL2/MCP-1, CD106/VCAM-1, CD54/ICAM-1, Collagen I, Collagen III, CXCL10/IP-10, CXCL11/I-TAC, CXCL8/IL-8, CXCL9/MIG, EGFR, M-CSF, MMP-1, PAI-I, Proliferation_72hr, SRB, TIMP-1, TIMP-2
KF3CTDermatitis, PsoriasisDermal fibroblasts + KeratinocytesCCL2/MCP-1, CD54/ICAM-1, CXCL10/IP-10, CXCL8/IL-8, CXCL9/MIG, IL-1 α, MMP-9, PAI-I, SRB, TIMP-2, uPA
LPSCardiovascular Disease, Chronic InflammationPeripheral blood mononuclear cells + Venular endothelial cellsCCL2/MCP-1, CD106/VCAM-1, CD141/Thrombomodulin, CD142/Tissue Factor, CD40, CD62E/E-Selectin, CD69, CXCL8/IL-8, IL-1 α, M-CSF, sPGE2, SRB, sTNF-α
MyoFChronic Inflammation, Fibrosis, Matrix Remodeling, Wound HealingLung fibroblastsbFGF, CD106/VCAM-1, Collagen I, Collagen III, Collagen IV, CXCL8/IL-8, Decorin, MMP-1, PAI-I, SRB, TIMP-1, α-SM Actin
SAgAutoimmune Disease, Chronic InflammationPeripheral blood mononuclear cells + Venular endothelial cellsCCL2/MCP-1, CD38, CD40, CD62E/E-Selectin, CD69, CXCL8/IL-8, CXCL9/MIG, PBMC Cytotoxicity, Proliferation, SRB